@article{hopfner_allogeneic_2021,
	title = {Allogeneic {BK} {Virus}-{Specific} {T}-{Cell} {Treatment} in 2 {Patients} {With} {Progressive} {Multifocal} {Leukoencephalopathy}},
	volume = {8},
	issn = {2332-7812},
	url = {http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000001020},
	doi = {10.1212/NXI.0000000000001020},
	abstract = {Objective
              Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating opportunistic infection of the brain caused by the ubiquitously distributed JC polyomavirus. There are no established treatment options to stop or slow down disease progression. In 2018, a case series of 3 patients suggested the efficacy of allogeneic BK virus-specific T-cell (BKV-CTL) transplantation.
            
            
              Methods
              Two patients, a bilaterally lung transplanted patient on continuous immunosuppressive medication since 17 years and a patient with dermatomyositis treated with glucocorticosteroids, developed definite PML according to AAN diagnostic criteria. We transplanted both patients with allogeneic BKV-CTL from partially human leukocyte antigen (HLA) compatible donors. Donor T cells had directly been produced from leukapheresis by the CliniMACS IFN-γ cytokine capture system. In contrast to the previous series, we identified suitable donors by HLA typing in a preexamined registry and administered 1 log level less cells.
            
            
              Results
              Both patients' symptoms improved significantly within weeks. During the follow-up, a decrease in viral load in the CSF and a regression of the brain MRI changes occurred. The transfer seemed to induce endogenous BK and JC virus-specific T cells in the host.
            
            
              Conclusions
              We demonstrate that this optimized allogeneic BKV-CTL treatment paradigm represents a promising, innovative therapeutic option for PML and should be investigated in larger, controlled clinical trials.
            
            
              Classification of Evidence
              This study provides Class IV evidence that for patients with PML, allogeneic transplant of BKV-CTL improved symptoms, reduced MRI changes, and decreased viral load.},
	language = {en},
	number = {4},
	urldate = {2022-02-14},
	journal = {Neurology - Neuroimmunology Neuroinflammation},
	author = {Hopfner, Franziska and Möhn, Nora and Eiz-Vesper, Britta and Maecker-Kolhoff, Britta and Gottlieb, Jens and Blasczyk, Rainer and Mahmoudi, Nima and Pars, Kaweh and Adams, Ortwin and Stangel, Martin and Wattjes, Mike P. and Höglinger, Günter and Skripuletz, Thomas},
	month = jul,
	year = {2021},
	keywords = {peer-reviewed},
	pages = {e1020},
}